Polymyxin B and colistin are two closely related peptide antibiotics. Both act on the outer membrane of gram-negative bacteria, and WHO notes increasing colistin use for serious infections. This guide covers both, using FDA labels, trials and WHO and CDC sources checked on November 17, 2026.
Quick answer: Polymyxin B and colistin (polymyxin E) are prescription peptide antibiotics for serious gram-negative infections, such as Pseudomonas aeruginosa. Kidney injury and nerve toxicity are their main label risks. Two large trials found that adding meropenem to colistin did not significantly improve outcomes. The mcr-1 gene lets colistin resistance spread between bacteria.
Vitrapep does not sell polymyxin B or colistin; this page is a reference summary of published research and regulatory information.
What are polymyxin B and colistin?
The polymyxins are a family of peptide antibiotics. Polymyxin B and colistin both have FDA-approved products. The polymyxin B label calls it a basic polypeptide antibiotic made by Bacillus polymyxa. It is the sulfate salt of polymyxins B1 and B2 (Xellia polymyxin B label, 2026). PubChem quotes DrugBank and MeSH: colistin is a “cyclic polypeptide antibiotic from Bacillus colistinus,” made of polymyxins E1 and E2 (PubChem CID 5311054).
Why are they peptides? Each is a chain of amino acids, partly closed into a ring, with a fatty acid tail. The NCI Thesaurus, quoted in PubChem, describes polymyxin B as having a “cyclic peptide portion” and a “fatty acid portion” (PubChem CID 49800004). Our overview of types of peptides explains cyclic peptides.
The drug product for colistin is colistimethate sodium, which its label calls “a polypeptide antibiotic.” Its chemical name, pentasodium colistinmethanesulfonate, marks it as a methanesulfonate form of colistin (Coly-Mycin M label, 2026).
Polymyxin B and colistin: key facts
| Fact | Polymyxin B | Colistin (polymyxin E) |
|---|---|---|
| Structure type | Cationic cyclic polypeptide with fatty acid tail (polymyxins B1 and B2) | Cyclic polypeptide (polymyxins E1 and E2) |
| Class | Polymyxin antibacterial | Polymyxin antibacterial |
| Molecular formula (PubChem) | C56H98N16O13 | C52H98N16O13 |
| Molecular weight (PubChem) | 1,203.5 g/mol | 1,155.4 g/mol |
| First FDA approval | Earliest verified: June 29, 1964 (ANDA 060716) | June 4, 1970 (Coly-Mycin M, NDA 050108) |
| Brand names (US) | Generic polymyxin B labels | Coly-Mycin M; generic colistimethate labels |
How do polymyxin B and colistin work?
Gram-negative bacteria have an outer membrane coated with lipopolysaccharide (LPS), which carries negative charges. Polymyxins carry positive charges. The NCI Thesaurus states that polymyxin B “binds to the negatively charged site in the lipopolysaccharide layer.” Its fatty acid portion then “dissolves in the hydrophobic region of the bacterial cell membrane.”
The result is a detergent-like effect. The polymyxin B label states that “Polymyxins increase the permeability of bacterial cell membrane leading to death of the cell.” The Coly-Mycin M label calls colistimethate “a surface active agent which penetrates into and disrupts the bacterial cell membrane.”
What are polymyxin B and colistin approved for?
Polymyxin B. The Xellia label lists acute infections caused by susceptible strains of Pseudomonas aeruginosa, including infections of the urinary tract, meninges and bloodstream. It also lists, when less toxic drugs are ineffective or contraindicated:
- Haemophilus influenzae meningeal infections;
- Escherichia coli urinary tract infections;
- Aerobacter aerogenes bacteremia; and
- Klebsiella pneumoniae bacteremia.
Colistimethate. The Coly-Mycin M label covers “acute or chronic infections due to sensitive strains of certain gram-negative bacilli.” It names Enterobacter aerogenes, E. coli, Klebsiella pneumoniae and P. aeruginosa. It states that it “is not indicated for infections due to Proteus or Neisseria.”
What does the key evidence show?
Both drugs were approved before modern trial standards. Recent trials asked whether pairing colistin with a carbapenem helps against highly resistant bacteria. The two trials enrolled patients. The mcr-1 study tested bacteria from animals, meat and patients.
AIDA trial. This open-label randomized trial in Israel, Greece and Italy enrolled 406 adults with carbapenem-resistant gram-negative infections. It compared colistin alone with colistin plus meropenem. Clinical failure at day 14 was 79% (156 of 198) with colistin alone and 73% (152 of 208) with the combination. The difference was not significant: risk ratio 0.93 (95% CI 0.83 to 1.03) (Paul et al., 2018; NCT01732250).
OVERCOME trial. This international, double-blind, placebo-controlled trial randomized 464 patients with pneumonia or bloodstream infection. The bacteria were extensively drug-resistant Acinetobacter baumannii or P. aeruginosa, or carbapenem-resistant Enterobacterales. Mortality at 28 days was 43% with colistin alone and 37% with colistin plus meropenem (P = 0.17) (Kaye et al., 2023; NCT01597973).
The mcr-1 discovery. A 2016 study from China described MCR-1, “a member of the phosphoethanolamine transferase enzyme family,” carried on a plasmid. The gene was found in E. coli from 78 of 523 raw meat samples (15%) and 166 of 804 animals (21%). It also appeared in 16 of 1,322 samples (1%) from hospital inpatients. The plasmid transferred to other E. coli in the lab (Liu et al., 2016).
What side effects do the labels list?
Polymyxin B has a boxed warning. It covers nephrotoxicity, neurotoxicity and respiratory paralysis from neuromuscular blockade. It also warns against combining polymyxin B with other kidney- or nerve-toxic drugs, naming aminoglycosides and colistin. Listed adverse reactions include kidney effects, electrolyte disturbances, flushing, dizziness, drowsiness, tingling, apnea, drug fever and hives.
Colistimethate has no boxed warning on the Coly-Mycin M label. Its warnings state that “Nephrotoxicity can occur” and that “Transient neurological disturbances may occur.” Respiratory arrest has been reported. Listed adverse reactions include tingling of the extremities and tongue, slurred speech, dizziness, vertigo, seizures, respiratory distress and apnea.
Resistance is a central concern. WHO’s 2024 List of Medically Important Antimicrobials places polymyxins in its highest priority critically important group. It cites rising colistin use for serious infections, transmissible mcr genes and spread of resistant bacteria through the food chain (WHO, 2024).
What is their regulatory status, and how are they used in research?
Both are prescription drugs in the United States. DailyMed lists current polymyxin B labels from Xellia and Hikma, and colistimethate labels including Coly-Mycin M from Par Health, updated in 2026. Drugs@FDA lists the two early applications cited above as discontinued, while later products remain on the market.
Both drugs also serve as lab tools. CDC guidance on gonorrhea culture describes selective media with vancomycin, colistin and an antifungal agent, which suppress other microbes (CDC, 2002). Polymyxin B is used to neutralize endotoxin in cell assays. In one in vitro study with human immune cells, polymyxin B “was able to neutralize the effect of endotoxin” (Cardoso et al., 2007).
Frequently asked questions about polymyxin B and colistin
Is colistin the same as polymyxin B?
No, but they are close relatives. Colistin is polymyxin E. Both disrupt the bacterial membrane, and the polymyxin B boxed warning names colistin among drugs not to combine with it.
Is polymyxin B a peptide?
Yes. It is a cationic cyclic polypeptide with a fatty acid tail, a mix of polymyxins B1 and B2.
Why is colistin called a last-resort antibiotic?
WHO describes polymyxins as limited therapy for infections with multidrug-resistant Enterobacterales, Acinetobacter and Pseudomonas. It ranks them in its highest priority critically important group.
What is mcr-1?
A gene for a phosphoethanolamine transferase that causes colistin resistance. It sits on a plasmid, so it can pass between bacteria.
Does adding meropenem to colistin help?
Not significantly in the AIDA and OVERCOME trials. Neither found a significant benefit for the combination on its primary outcome.
What to know now
- Structure: cationic cyclic polypeptides with a fatty acid tail; polymyxin B 1,203.5 g/mol, colistin 1,155.4 g/mol (PubChem).
- Mechanism: bind LPS on gram-negative bacteria and disrupt the membrane.
- Approval: polymyxin B by 1964; Coly-Mycin M in 1970; both prescription only.
- Safety: polymyxin B boxed warning for kidney and nerve toxicity; colistimethate warns of both.
- Evidence: no significant benefit from adding meropenem in AIDA (406 patients) or OVERCOME (464 patients).
- Resistance: plasmid mcr-1; WHO ranks polymyxins highest priority critically important.
What we’re watching
The next WHO List of Medically Important Antimicrobials. DailyMed label updates for both drugs. Related guides: bacitracin, vancomycin and daptomycin.